✉news BusinessRetail first seen 4 h ago, last 53 min ago, peak #16
Retail Traders Eye SLS and IBRX After Moderna Joins Nasdaq-100
Original: SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Retail investors are buzzing about small-cap biotech stocks Sellas Life Sciences (SLS) and ImmunityBio (IBRX) after Moderna (MRNA) earned a spot in the Nasdaq-100 index. Traders are speculating that one of these smaller biotechs could be the next index addition, with some betting 'it will be SLS next' as index inclusion typically brings fund inflows and a share price boost.
Why now: Moderna's Nasdaq-100 inclusion has sparked speculation among retail traders about which biotech stock could be added to the index next.
Sellas Life SciencesImmunityBioModernaNasdaq-100
Rank over time, top of the chart is #1. 4 snapshots from 4 h ago to 53 min ago.
Evidence
- SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’ · Stocktwits
API: https://socialmediatrends-api.osmike.com/v1/trends/928514